Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 40 MANNING RD BILLERICA MA 01821 |
Tel: | N/A |
Website: | https://www.bruker.com |
IR: | See website |
Key People | ||
Frank H. Laukien Chairman of the Board, President, Chief Executive Officer | Gerald N. Herman Chief Financial Officer, Executive Vice President | Falko Busse President, Bruker BioSpin Group |
Burkhard Prause President and Chief Executive Officer, Bruker Energy and Supercon Technologies, Inc | Juergen Srega President of Bruker CALID Group and Bruker Daltonics Division | Mark Robert Munch Executive Vice President, President of Bruker Nano Group and Bruker Nano Surfaces Division |
Business Overview |
Bruker Corporation is a developer, manufacturer and distributor of scientific instruments and analytical and diagnostic solutions. The Company's BSI BioSpin segment designs, manufactures, and distributes enabling life science tools based on magnetic resonance technology. Its BSI CALID segment designs, manufactures and distributes life science mass spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions. Its BSI Nano segment designs, manufactures and distributes advanced X-ray instruments, atomic force microscopy instrumentation, advanced fluorescence optical microscopy instruments. Its Bruker Energy & Supercon Technologies (BEST) segment develops and manufactures superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare and big science research. It offers scanning transmission electron microscopes (STEM). It also offers advanced research Raman microscopy systems. |
Financial Overview |
For the fiscal year ended 31 December 2023, Bruker Corp revenues increased 17% to $2.96B. Net income increased 44% to $427.2M. Revenues reflect BSI NANO segment increase of 20% to $941.9M, BSI CALID segment increase of 17% to $960.4M, BSI BioSpin segment increase of 15% to $798.5M, China segment increase of 33% to $528.1M, Europe segment increase of 18% to $699.7M, United States segment increase of 12% to $777.7M. |
Employees: | 9,707 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $13,726M as of Dec 31, 2023 |
Annual revenue (TTM): | $2,965M as of Dec 31, 2023 |
EBITDA (TTM): | $649.10M as of Dec 31, 2023 |
Net annual income (TTM): | $427.20M as of Dec 31, 2023 |
Free cash flow (TTM): | $213.80M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $793.20M as of Dec 31, 2023 |
Shares outstanding: | 137,671,143 as of Feb 25, 2024 |
Index Membership: | S&P 400 Mid Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |